Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial
Authors:
- 1 May 2021
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 148, 382-394
Abstract
No abstract availableKeywords
Funding Information
- Merck Sharp and Dohme Ltd
This publication has 20 references indexed in Scilit:
- Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast CancerClinical Cancer Research, 2018
- Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor studyBreast Cancer Research and Treatment, 2017
- Immuno-oncology Clinical Trial Design: Limitations, Challenges, and OpportunitiesClinical Cancer Research, 2017
- Advances in the treatment of advanced oestrogen-receptor-positive breast cancerThe Lancet, 2017
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeuticsThe Lancet Oncology, 2017
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 StudyJournal of Clinical Oncology, 2016
- Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to VJournal of Clinical Oncology, 2016
- Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasisOncotarget, 2016
- Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a TaxaneJournal of Clinical Oncology, 2015
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyThe Lancet, 2011